Introduction {#S1}
============

Gastric cancer is the fourth most common malignant tumor in the world ([@B45]). Early diagnosis and treatment are critical to improve the prognosis and reduce the mortality of patients with gastric cancer. Identifying important regulatory molecules in gastric cancer can provide valuable information for finding biomarkers for diagnosis and prognosis and for therapeutic targets.

In recent years, long non-coding RNAs (lncRNAs) have been shown to play a role in gene regulation. Abnormally expressed lncRNAs have been found in common malignant tumors, such as liver cancer and breast cancer ([@B8]; [@B1]; [@B61]). These lncRNAs regulate tumor cells via various signaling pathways, such as Notch, mTOR, NF-κB, Wnt, and TGF-β, and play an important role in cell division, differentiation, apoptosis, invasion, and other processes ([@B46]; [@B29]; [@B4]). Many studies have shown that lncRNAs are also closely related to the occurrence, development, and metastasis of gastric cancer ([@B11]; [@B51]; [@B62]; [@B14]; [@B42]; [@B69]). Compared with mRNA, lncRNA expression is more tissue specific ([@B56]; [@B7], [@B6]; [@B3]), which may provide new information for finding specific biomarkers for gastric cancer.

Long non-coding RNAs are involved in gastric cancer mechanisms by directly promoting or inhibiting cell growth, migration, invasion, or by regulating oncogenes and tumor suppressor genes ([@B11]; [@B56]; [@B62]; [@B5]). For example, H19 exhibits carcinogenic effects in gastric cancer. [@B60] demonstrated that H19 is significantly increased in human gastric cancer tissues and AGS cell lines and accelerates gastric cancer cell proliferation. HOTAIR can promote the development of cancer by silencing the expression of miR-34a, inducing SNAIL, PI3K/Akt, and NF-κB signaling pathways ([@B32]). Xu et al. found that FOXM and PVT form a positive feedback loop to promote gastric cancer proliferation and metastasis ([@B24]).

The expression of lncRNAs is related to the clinicopathological features of gastric cancer patients, such as TNM staging, tumor size and metastasis, differentiation, and infiltration ([@B58], [@B59]; [@B51]; [@B15]; [@B72]). Abnormally expressed lncRNAs can be used as biomarkers for the early diagnosis of gastric cancer. H19 is overexpressed in both gastric cancer and gastric cancer cell lines, and the same trend can be observed in plasma ([@B2]). AA174084 is less expressed in most gastric cancer tissues but is highly expressed in gastric juice and is associated with patient age, Borrmann typing, infiltration, and lymphatic metastasis ([@B44]). GACAT1 is significantly associated with lymph node metastasis and distant metastasis in gastric cancer tissues and may play an important role in gastric cancer metastasis ([@B50]).

Abnormally expressed lncRNAs can also be used to predict prognosis and monitor therapeutic response ([@B66], [@B65]; [@B71]). The reduced expression of MEG3 in gastric cancer tissues is associated with TNM staging, depth of invasion, and tumor size and may indicate poor prognosis ([@B28]). The overexpression of HOTAIR in gastric cancer is an effective predictor of tumor progression, associated with venous invasion, lymph node metastasis, and shortened survival in patients with diffuse gastric cancer ([@B31]). [@B18] found that GAPLINC is highly expressed in gastric cancer and can be used as a prognostic marker. The lower expression level of GAS5 in gastric cancer is also associated with poor prognosis ([@B49]). To obtain higher diagnostic accuracy and prognostic predictive effects, some studies have focused on combining multiple lncRNAs into a more efficient biomarker, such as the groups CTD-2616J11.14, RP1-90G24.10, RP11-150O12.3, RP11-1149O23.2, and MLK7-AS1 ([@B43]).

In summary, the molecular mechanisms of some individual gastric cancer-related lncRNAs have been discovered, but a systematic understanding of the relationship between lncRNAs and gastric cancer is still lacking. With the advance of high-throughput RNA sequencing (RNA-seq), the whole transcriptome, including lncRNAs, can be comprehensively discovered ([@B20]; [@B70]). More unannotated and tissue-specific lncRNAs can be identified by the *ab initio* assembly method ([@B58]; [@B19]; [@B52]; [@B64]). Further investigation and functional analysis are also essential for these novel lncRNAs.

In this paper, the GSE85467 dataset from the Gene Expression Omnibus (GEO), including RNA-seq, DNA-methylation array, and copy number variation (CNV) array data, was integrated and leveraged to study the potential function of lncRNAs in gastric cancer ([@B39]). First, we aligned the RNA-seq data, assembled the transcriptome, and screened both annotated genes and the newly assembled lncRNAs (candidate lncRNAs) presented in the transcriptome. Next, we identified lncRNAs that were differentially expressed between gastric cancer and paracancerous tissues. The basic features of the candidate lncRNAs, such as transcript length, expression abundance, evolutionary conservation, and genomic location, were characterized and compared with the corresponding features of the annotated lncRNAs and protein-encoding genes in GENCODE v19. Then, we analyzed the factors that may affect the expression level of lncRNA and predicted the potential function of lncRNA in gastric cancer. Finally, we looked for possible biomarkers of gastric cancer prognosis.

Results {#S2}
=======

Candidate lncRNA Identification {#S2.SS1}
-------------------------------

In this paper, RNA-seq sequencing raw data (GSE85467) of eight gastric cancer tissues and paracancerous healthy tissues (16 samples) were downloaded from the NCBI GEO database. The dataset contained a total of 3,450,746,608 sequencing reads. Short sequences were aligned to the human reference genome GRCh37/hg19 by TopHat. The average mappable rate of the raw reads reached 77.78%.

A total of 92.6% of the 13,870 lncRNAs (23,898 transcripts) annotated in GENCODE v19 were detected in gastric cancer and paracancerous healthy tissue samples, which indicates that the sequencing depth of the RNA-seq dataset was sufficient for studying the function of lncRNAs in gastric cancer. This also suggests the correctness of the previous data processing steps, such as sequence alignment and transcript *ab initio* assembly.

Using the annotated non-coding RNAs and protein-coding genes in GENCODE v19 as a reference, a total of 1,854 newly assembled lncRNAs (2,039 transcripts) were screened out through a rigorous screening process ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The results of each step of the screening process are shown in [Table 1](#T1){ref-type="table"}. The novel lncRNAs were designated "candidate lncRNAs." These candidate lncRNAs may be tissue-specific and function in gastric cancer tissues.

![Workflow of candidate lncRNA screening.](fcell-08-00557-g001){#F1}

###### 

Remaining transcripts after each filter step.

  Step                                                 Filters                 Parameters             Number of transcripts   
  ---------------------------------------------------- ----------------------- ---------------------- ----------------------- -------------
  1                                                    Merged transcriptome    NA                     327,364                 
  2                                                    Length of transcripts   Length \> 200 nt       24,836                  
                                                       GENCODE v19             No overlap                                     
                                                       annotation                                                             
  3                                                    Annotation by           Exon number            Monoexonic              Multiexonic
                                                       exon number                                    19,169                  5,667
  4                                                    Distance                Distance \> 2,000 nt   17,928                  
  5                                                    Expression              Max (FPKM) \> 0.5      2,797                   
  6                                                    Novel transcripts       NA                     8,464                   
  7                                                    CPC                     Default                2,039                   
  Total number of newly assembled lncRNA transcripts   2,039                                                                  
                                                       (1,854 lncRNA genes)                                                   

Basic Characteristics and Transcriptional Activity of the Candidate lncRNAs {#S2.SS2}
---------------------------------------------------------------------------

Using the annotated non-coding RNAs and protein-coding genes in GENCODE v19 as a reference, a total of 1,854 newly assembled lncRNAs (2,039 transcripts) were screened out through a rigorous screening process ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The results of each step of the screening process are shown in [Table 1](#T1){ref-type="table"}. The novel lncRNAs were designated "candidate lncRNAs." These candidate lncRNAs may be tissue-specific and function in gastric cancer tissues.

According to the location of the candidate lncRNAs relative to that of the protein-coding genes, the candidate lncRNAs were classified into four categories: 83.4% of the candidate lncRNAs were located in the intergenic regions and classified as intergenic lncRNAs; 15.2% of the candidate lncRNAs overlapped with the exons of the protein-coding genes or non-coding RNAs on the antisense strand and were classified as antisense lncRNAs; 1.3% of the candidate lncRNAs located in the same strand as the protein-coding gene within \<2,000 nt, as cis-elements of the protein-coding gene, were classified as sense lncRNAs; only a small proportion (0.1%) of the candidate lncRNAs were completely located in the intron region of the protein-coding genes and were classified as intronic lncRNAs. The proportion of genomic location annotation of candidate lncRNAs was consistent with the statistical results in the literature.

Basic features of candidate lncRNAs, such as transcript length, expression abundance, conservation of exon/intron regions, and the transcriptional activity marker H3K4me3 and H3K27ac signals, were characterized and compared to the annotated lncRNAs and protein-coding genes in GENCODE v19 ([Figure 2](#F2){ref-type="fig"}).

![Basic features of the candidate lncRNAs. **(A)** Length distribution of the transcripts. **(B)** Maximum expression level (FPKM) of the transcripts. **(C)** Exonic/intronic conservation of the transcripts. **(D)** H3K4me3 enrichment near the TSS of candidate lncRNAs, GENCODE lncRNAs, and protein-coding genes. **(E)** H3K27ac enrichment near the TSS of candidate lncRNAs, GENCODE lncRNAs and protein-coding genes.](fcell-08-00557-g002){#F2}

As shown in [Figure 2A](#F2){ref-type="fig"}, the transcript lengths of the candidate lncRNAs were slightly shorter than those of the protein-coding genes. In the candidate lncRNAs, the proportion of transcripts of 1,000--2,000 nt length was more than that of the GENCODE-annotated lncRNAs. The proportion of transcripts that were longer than 2,000 nt was similar, indicating that the RNA-seq depth was sufficient for *de novo* lncRNA assembly.

[Figure 2B](#F2){ref-type="fig"} shows that the expression levels of the candidate lncRNAs were generally not high, which explains the possible reasons why these candidate lncRNAs were not found in previous studies.

[Figure 2C](#F2){ref-type="fig"} shows that both the exon and intron regions of the candidate lncRNAs were less conserved than the corresponding regions of the protein-coding genes and were similar to the GENCODE-annotated lncRNAs. The conservation of exons was higher than that of introns. This result is logical and consistent with the results of previous studies.

In summary, the selected candidate lncRNAs were basically consistent with the characteristics of the known lncRNAs in GENCODE, which is consistent with the literature and biological principles, which indicates that the previously unexpressed lncRNAs identified in this paper are authentic and reliable.

To verify whether the candidate lncRNAs were transcribed in gastric cancer tissues, ChIP-seq data from the same gastric cancer tissues were used to capture the transcriptional activity signals near the transcription start sites (TSS).

As shown in [Figures 2D,E](#F2){ref-type="fig"}, two epigenetic signals, H3K4me3 and H3K27ac, were enriched at the TSS in all transcripts, including candidate lncRNAs, GENCODE-annotated lncRNAs, and protein-coding genes. Both histone modifications were associated with transcriptional activation. The transcriptional activity signal intensity near the protein-coding gene TSS was the highest, and the signal intensity near the TSS of the candidate lncRNAs was lower than that of the GENCODE-annotated lncRNAs, which is consistent with the generally low expression level of the candidate lncRNAs ([Figure 2B](#F2){ref-type="fig"}). This result indicates that in gastric cancer tissues, the transcriptional activity of these lncRNAs is regulated to different degrees.

Differentially Expressed lncRNAs Between Cancerous and Normal Tissues {#S2.SS3}
---------------------------------------------------------------------

As shown in [Figures 2D,E](#F2){ref-type="fig"}, two epigenetic signals, H3K4me3 and H3K27ac, were enriched at the TSS in all transcripts, including candidate lncRNAs, GENCODE-annotated lncRNAs, and protein-coding genes. Both histone modifications were associated with transcriptional activation. The transcriptional activity signal intensity near the protein-coding gene TSS was the highest, and the signal intensity near the TSS of the candidate lncRNAs was lower than that of the GENCODE-annotated lncRNAs, which is consistent with the generally low expression level of the candidate lncRNAs ([Figure 2B](#F2){ref-type="fig"}). This result indicates that in gastric cancer tissues, the transcriptional activity of these lncRNAs is regulated to different degrees.

In this paper, differential expression analysis was carried out using the DEseq2 package in the R environment. This method is able to analyze candidate lncRNAs with relatively low expression. A total of 328 upregulated lncRNAs in gastric cancer tissues and 192 downregulated lncRNAs were found, of which 42 and 29 were candidate lncRNAs, respectively ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}).

These differentially expressed lncRNAs may play an important role in the occurrence and development of gastric cancer. [Table 2](#T2){ref-type="table"} lists the typical cases of differentially expressed GENCODE lncRNAs and candidate lncRNAs. Up/downregulated lncRNAs with \| log2(fold_change)\| \> 3 and 5 smallest *p*-values were illustrated. Some of the differentially expressed lncRNAs in our results have also been reported in previous gastric cancer studies, such as PVT1 (ENSG00000249859.3), which is upregulated in gastric cancer tissues, promotes gastric cancer cell division and angiogenesis, and is associated with a poor prognosis ([@B24]).

###### 

Typical up/downregulated lncRNAs in gastric cancer.

  Gene ID              Gene symbol     Up/down   log2(fold_change)   *P*-value   q-value
  -------------------- --------------- --------- ------------------- ----------- ----------
  ENSG00000269495.1    CTB-147C22.8    Up        7.379               1.63E−15    1.31E−11
  ENSG00000128683.9    GAD1            Up        4.751               9.39E−12    3.36E−08
  ENSG00000136231.9    IGF2BP3         Up        4.102               2.02E−11    6.50E−08
  ENSG00000249550.2    RP11-438N16.1   Up        5.613               8.07E−11    2.16E−07
  ENSG00000249859.3    PVT1            Up        3.433               5.39E−08    4.21E−05
  ENSG00000233441.2    CYP2AB1P        Down      --5.272             6.49E−14    2.98E−10
  ENSG00000139988.5    RDH12           Down      --3.857             4.74E−11    1.39E−07
  ENSG00000100095.14   SEZ6L           Down      --3.220             3.98E−08    3.41E−05
  ENSG00000264785.1    RP11-311F12.2   Down      --4.375             5.50E−08    4.21E−05
  ENSG00000146151.8    HMGCLL1         Down      --3.180             7.64E−08    5.26E−05

As shown in [Figure 3A](#F3){ref-type="fig"}, hierarchical clustering analysis was performed on the differentially expressed lncRNAs. The heatmap illustrates that differentially expressed lncRNAs can accurately distinguish gastric cancer tissue samples from normal tissue samples, suggesting the potential role of these differentially expressed lncRNAs in the development and progression of gastric cancer.

![Differentially expressed lncRNAs between cancer and normal tissues. **(A)** Differentially expressed lncRNA clustering analysis. Rows are lncRNAs, and columns are samples. Blue denotes downregulation in gastric cancer and red denotes upregulation in gastric cancer. **(B)** GSEA enrichment analysis results. **(C)** Deletions and amplifications in gastric cancer genomes.](fcell-08-00557-g003){#F3}

To verify the reliability of the differentially expressed lncRNAs, we obtained gene expression data from 171 gastric cancer patients from the TCGA-STAD project, including 170 primary gastric cancer tissues and 20 paracancerous tissues. Then, we used GSEA (v 3.0) ([@B48]) to analyze the differentially expressed lncRNA enrichment in the TCGA gene expression data.

The results are shown in [Figure 3B](#F3){ref-type="fig"}. The genes present in all TCGA samples were sorted according to the expression levels in the tumor and normal samples. When analyzing each gene of the TCGA expression dataset, if a gene was also a differentially expressed lncRNA in our result, the enrichment score (ES) increased, or vice versa. [Figure 3B](#F3){ref-type="fig"} illustrates that the upregulated lncRNAs in the gastric cancer tissues were enriched in the high expression region of the TCGA tumor dataset, and the downregulated lncRNAs in the gastric cancer tissues were enriched in the high expression region of the TCGA normal dataset. This indicates that the differentially expressed lncRNAs screened in this paper also have extensive aberrant expression in TCGA gastric cancer samples.

To further explore the causes of the differential expression. We analyzed the DNA methylation data and CNV data from the same sample with RNA-seq data and investigated the possible genomic mechanism underlying the differential expression of the lncRNAs ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}).

The CNV data were analyzed with the GISTIC algorithm. Two significantly amplified DNA regions and eight significantly deleted DNA regions (q-value \< 0.25) were found in the gastric cancer genomes ([Figure 3C](#F3){ref-type="fig"}). By comparing the genomic locations of the differentially expressed lncRNAs with the CNV regions, we found the lncRNA "*RP11-75C9.1*" located in a deletion region. The expression level of this lncRNA was downregulated in gastric cancer tissues. No differentially expressed lncRNA was found in the significantly amplified region.

Based on DNA methylation microarray data, we screened the DNA methylation sites located in the differentially expressed lncRNA promoter regions and calculated the Pearson correlation coefficient (pcc) between the methylation level and lncRNA expression level in all samples. We found that the expression level of 90 differentially expressed lncRNAs correlated with DNA methylation signals in the corresponding promoter region (pcc \< -0.3). There were 56 upregulated lncRNAs and 34 downregulated lncRNAs, including two newly identified candidate lncRNAs. Typical cases are listed in [Table 3](#T3){ref-type="table"}.

###### 

Potential DNA methylation-regulated lncRNAs in gastric cancer.

  Gene ID              Gene symbol    Up/down   CpG          pcc
  -------------------- -------------- --------- ------------ -----------
  ENSG00000249859.3    PVT1           Up        cg05480350   --0.8624
  ENSG00000196335.8    STK31          Up        cg14898779   --0.81715
  ENSG00000248538.2    RP11-10A14.5   Up        cg24270182   --0.78429
  ENSG00000185201.12   IFITM2         Up        cg09026253   --0.76839
  ENSG00000018280.12   SLC11A1        Up        cg16926316   --0.76340
  ENSG00000166573.4    GALR1          Down      cg04534765   --0.64735
  ENSG00000152953.8    STK32B         Down      cg22551741   --0.567
  ENSG00000234616.4    JRK            Down      cg06521562   --0.55163
  ENSG00000133101.5    CCNA1          Down      cg05089090   --0.54299
  ENSG00000257935.2    RP11-82C23.2   Down      cg20670075   --0.51918

Functional Analysis of lncRNAs in Gastric Cancer {#S2.SS4}
------------------------------------------------

To investigate the functional role of lncRNA in the occurrence and development of gastric cancer, we constructed an mRNA--lncRNA coexpression network using the MCL algorithm. The network contained lncRNAs and protein-coding genes that were highly correlated at the expression level. The function of the protein-coding genes in each cluster was analyzed to predict the potential function of the lncRNAs.

All protein-coding genes and lncRNAs were clustered into 27 classes. Each class contained at least 45 genes. The whole network contained 6,734 protein-coding genes, 1,323 GENCODE-annotated lncRNAs, and 1,072 candidate lncRNAs, including 266 differentially expressed lncRNAs, forming 2,743,354 gene/lncRNA interactions.

For each cluster, GO analysis and KEGG pathway enrichment analysis were performed on the protein-coding genes. Then, the potential functions were assigned to the clusters, predicting the potential functions of the coexpressed lncRNAs in the clusters.

Based on the GO and KEGG annotation, six clusters (clusters 1, 2, 3, 6, 8, and 22) may have functions related to the occurrence, development, and metastasis of gastric cancer ([Figure 4](#F4){ref-type="fig"}). A total of 4,737 protein-coding genes, 701 GENCODE-annotated lncRNAs, and 413 candidate lncRNAs were in these six clusters, including 139 differentially expressed lncRNAs, accounting for 52.3% of all differentially expressed lncRNAs in the coexpression network.

![LncRNA functional analysis, including a total of 4,737 protein-coding genes, 701 GENCODE-annotated lncRNAs, and 413 candidate lncRNAs, the protein-coding genes and lncRNAs were clustered in six clusters. **(A)** The major clusters of the protein-coding gene/lncRNA coexpression network, where dark and light blue dots represent lncRNAs, light orange dots represent protein-coding genes, white dots represent deregulated lncRNAs. **(B)** GO/KEGG enrichment of the six major clusters, in which cluster 1 was mainly involved in cell signaling, cluster 2 was mainly involved in cell cycle processes, cluster 3 mainly related to the metabolic process in the stomach, cluster 6 was mainly involved in angiogenesis, cluster 8 was mainly involved in the immune response, and cluster 22 was primarily associated with the retinoic acid (RA) receptor signaling pathway.](fcell-08-00557-g004){#F4}

Cluster 1 was mainly involved in cell signaling, such as the MAPK signaling and calcium ion pathways. The MAPK signaling pathway is critical for extracellular signal transduction into cellular responses and is involved in the development of cancer by regulating cell proliferation, differentiation, inflammation, and apoptosis ([@B68]). The regulation of calcium signaling plays an important role in cell function. The dysregulation of the calcium signaling pathway leads to abnormal cell division, transcriptional processes, and cell death ([@B47]), which are also associated with the development of gastric cancer.

Cluster 2 was mainly involved in cell cycle processes, such as DNA metabolism, DNA replication, and pathways associated with spliceosomes, which are related to the migration of gastric cancer cells.

Cluster 3 mainly related to the metabolic process in the stomach, such as the metabolism of organic acids, the metabolism of small molecules and the digestion and absorption of proteins.

Cluster 6 was mainly involved in angiogenesis, such as the vascular endothelial growth factor (VEGF) signaling pathway. Angiogenesis is critical for the development and metastasis of solid tumors ([@B12]), and VEGF plays a central role in angiogenesis in cancerous diseases ([@B27]). The genes in this cluster were also significantly enriched in the p53 signaling pathway.

Cluster 8 was mainly involved in the immune response, such as the activation of leukocytes and chemokines and T cell receptor signaling pathways. The immune response may contribute to tumor development by influencing the infiltration and migration processes of tumor cells ([@B13]).

Cluster 22 was primarily associated with the retinoic acid (RA) receptor signaling pathway. Previous studies have reported that RA is involved in many biological processes, such as cell growth, differentiation, and apoptosis ([@B17]). The dysregulation of these processes is closely related to the occurrence and development of cancer. Changes in the RA signaling pathway are closely related to many inflammatory and neoplastic pathologies, including breast cancer, hematological malignancies, skin cancer, gastric cancer, and lung cancer ([@B41]; [@B35]; [@B21]; [@B33]). Previous studies have found that RA can reduce the viability of gastric cancer cells in a concentration-dependent manner ([@B40]). It not only can significantly inhibit the proliferation of gastric cancer cells but also has a certain effect on the treatment of gastric cancer *in vivo* ([@B38]).

Prognostic Biomarkers for Gastric Cancer {#S2.SS5}
----------------------------------------

We further screened potential prognostic biomarkers for gastric cancer in the lncRNAs.

For each differentially expressed lncRNA, an expression cut-off value was set. Based on the cut-off value, the 170 patients from TCGA were divided into two groups: the high-expression group and the low-expression group. Then, the Kaplan--Meier 5-year survival analysis was performed based on the clinical information (current survival status, survival days before death) of the patients. A log rank test was conducted to analyze the significance.

As shown in [Figure 5](#F5){ref-type="fig"}, we found a differentially expressed lncRNA, AC004510.3 (ENSG00000267308.1) that could significantly distinguish 170 patients into two groups with different 5-year survival statuses. AC004510.3 is an intergenic lncRNA and is highly expressed in gastric cancer tissues. The expression level of AC004510.3 was significantly correlated with the survival time of gastric cancer patients (*P*-value = 0.0037). When the expression level of AC004510.3 in the gastric cancer tissues was higher than the cut-off value, the survival time of patients was significantly lower than that of patients with relatively low expression levels. This provides a possible prognosis prediction biomarker for gastric cancer patients.

![Kaplan--Meier survival analysis for the lncRNA AC004510.3, which is an intergenic lncRNA and is highly expressed in gastric cancer tissues. The lncRNA could significantly distinguish 170 patients into two groups with different 5-year survival statuses. The expression level was significantly correlated with the survival time of gastric cancer patients (*P*-value = 0.0037).](fcell-08-00557-g005){#F5}

Materials and Methods {#S3}
=====================

Data Source {#S3.SS1}
-----------

In this paper, we used (1) RNA-seq pair-end sequencing data from eight gastric cancer tissues and eight corresponding adjacent cancer tissues from the GEO database GSE85467 series ([@B39]). The detailed sample and clinical information are described in [Supplementary Tables S4](#SM1){ref-type="supplementary-material"}, [S5](#SM1){ref-type="supplementary-material"}. (2) DNA methylation microarray data (GSE76153) were derived from the same sample as the sample used for the RNA-seq data. (3) The CNV microarray data (GSE85466) were derived from the same sample as the sample used the RNA-seq data. (4) The analyzed ChIP-seq data (GSE76153) in the GSE85467 series were also used, which are the H3K4me3 (GSM1975173) and H3K27ac (GSM1975175) histone modification data.

Moreover, the gene expression data of 170 gastric cancer tissues and 28 adjacent cancer tissues from 171 gastric cancer patients were downloaded from the National Cancer Institute (NCI) Genomic Data Commons (GDC) Data Portal. The data were generated by the TCGA-STAD project ([@B53]).

RNA-Seq Data Processing {#S3.SS2}
-----------------------

The raw RNA-seq data were aligned and assembled by Tophat ([@B54]) and Cufflinks ([@B55]). The RNA-seq reads were aligned to the human reference genome GRCh37/hg19 with GENCODE v19 annotation ([@B16]). *Ab initio* assembly was conducted for each sample to identify previously unreported transcripts. Then, the transcriptomes of the 16 samples were integrated into a final transcriptome by the Cuffmerge component of the Cufflinks tool. Finally, the expression levels of both the protein-coding genes and lncRNAs were calculated by the Cuffnorm component of the Cufflinks tool.

Candidate lncRNA Screening {#S3.SS3}
--------------------------

Based on the GENCODE annotation, the transcripts present in the sample transcriptome were classified into three categories: protein-coding genes, annotated lncRNAs, and unannotated lncRNAs. The candidate lncRNAs were extracted from the unannotated lncRNAs by the following steps:

1.  Transcripts shorter than 200 nt or lacking strand information were removed.

2.  Transcripts overlapping annotated protein-coding genes or non-coding RNAs were removed.

3.  Mono-exon transcripts near (distance \< 2,000 nt) annotated protein-coding genes or non-coding RNAs were removed.

4.  Mono-exon transcripts with low expression levels (FPKM \< 0.5) in all samples were removed.

5.  Transcripts with high coding potential (CPC \> 0) were removed. The coding potential was calculated using the Coding Potential Calculator (CPC) tool ([@B23]).

ChIP-Seq Analysis {#S3.SS4}
-----------------

The corresponding ChIP-seq data (GSE76153) of two histone markers, H3K4me3 and H3K27ac, were used to check the transcriptional activity of the candidate lncRNAs. The "IRanges" and the "GenomicFeatures" ([@B26]) packages of the R environment were used to construct the histone modification peak and the TSS data. Then, we use the "ChipSeeker" ([@B63]) package to calculate and plot the signal intensities of the two histone modification signals around (up to 7,000 nt upstream and downstream) the TSS of each class of transcripts.

Differential Expression Analysis of the lncRNAs {#S3.SS5}
-----------------------------------------------

Differential expression analysis was conducted by the "DEseq2" ([@B34]) package in the R environment. The criteria were the logarithmic change in expression level \[\|log2(fold-change)\| \> 1, *P*-value \< 0.05, q-value \< 0.05\]. All transcripts in the integrated transcriptome were tested. Both protein-coding genes and lncRNAs that were differentially expressed between gastric cancer tissues and adjacent cancer tissues were identified.

DNA Methylation and CNV Data Analysis {#S3.SS6}
-------------------------------------

The β value of each CpG site in all samples was calculated using the "ChAMP" ([@B37]) package in the R environment to represent the methylation level. The methylation sites located in the differentially expressed lncRNA promoter regions (\<2,000 nt upstream of the TSS) were selected. The pcc was calculated between the expression level and the corresponding DNA methylation signal of each lncRNA in all samples.

We used GISTIC 2.0 ([@B36]) to determine significant DNA deletion or amplification.

DNA Methylation and CNV Data Analysis {#S3.SS7}
-------------------------------------

We employed a published method ([@B30]; [@B57]) to construct mRNA--lncRNA coexpression network. The network contained all differentially expressed protein-coding genes and lncRNAs, including both GENCODE-annotated genes and candidate lncRNAs. The detailed steps were as follows:

1.  For each lncRNA and protein-coding gene pair, we used the "WGCNA" ([@B25]) package in the R environment to calculate the pcc of the expression levels of the gene pairs across all samples. The *p*-value was corrected using the Benjamin Hochberg method by the "multtest" package.

2.  Next, the genes with highly correlated expression levels were clustered by the Markov clustering (MCL) algorithm ([@B10]). The corrected *p*-value was used as the weight of the edge connecting each pair of genes.

3.  Cytoscape ([@B22]) was used to visualize the clustering result.

GO and KEGG Pathway Analysis {#S3.SS8}
----------------------------

WebGestalt ([@B67])^[1](#footnote1){ref-type="fn"}^ was used to perform GO/KEGG pathway enrichment analyses for all protein-coding genes present in each coexpression network cluster.

Survival Analysis {#S3.SS9}
-----------------

We used the "survival" package in the R environment to perform the Kaplan--Meier analysis ([@B9]). The statistical significance of the results was analyzed by log rank test.

Discussion {#S4}
==========

To explore the potential role of lncRNAs in the development and metastasis of gastric cancer, RNA-seq, ChIP-seq, CNV chip, and DNA methylation ChIP data from 16 gastric cancer and adjacent healthy tissue samples were obtained. A series of analyses were carried out at the genomic and epigenetic levels.

In the 16 gastric cancer and paracancerous tissues, we discovered 1,854 lncRNAs that had not been previously annotated. By characterizing the transcript length, expression abundance, conservation, and transcriptional activity, we showed that the basic features of the candidate lncRNAs screened in this paper were similar to the annotated lncRNAs and thus were reliable.

We analyzed the differentially expressed genes in the gastric cancer tissues and adjacent healthy tissue samples. A total of 328 upregulated lncRNAs and 192 downregulated lncRNAs were screened in the gastric cancer tissues, of which 42 and 29 were candidate lncRNAs, respectively. The result of GSEA enrichment analysis indicated that the differentially expressed lncRNAs found in this study were also abnormally expressed in the gastric cancer tissues of the TCGA patients.

By analyzing the DNA methylation and CNV data of the same sample, it was found that the expression levels of some differentially expressed lncRNAs were significantly correlated with the DNA methylation signals on their promoter region. We also found a differentially expressed lncRNA located in the CNV region. These results suggest possible causes of the aberrant expression of lncRNAs in gastric cancer.

We used the mRNA--lncRNA coexpression network to predict the functions of differentially expressed lncRNAs and found that the differential expression of lncRNAs may affect the occurrence and metastasis of gastric cancer via various biological processes, such as cell signaling, cell cycle, immune response, metabolic processes, angiogenesis, and RA receptor regulation.

Finally, we found that the lncRNA *AC004510.3*, which was upregulated in gastric cancer tissues, was significantly correlated with the expression level of gastric cancer tissues and the survival time of the patients. Thus, it has the potential to become a prognostic biomarker for gastric cancer patients.

The pathogenesis of gastric cancer remains unclear. Most patients with gastric cancer often have no symptoms at an early stage and are not diagnosed until the late stage, missing the best treatment period. The results of this paper have deepened the systematic understanding of the function and role of lncRNAs in the occurrence and metastasis of gastric cancer. We hope these results will provide novel information regarding gastric cancer.
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